Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 23, 2025
Event: Entry into a Material Definitive Agreement (Warrant Inducement Transaction)
On July 23, 2025, Palisade Bio entered into an agreement with an accredited institutional holder to induce the exercise of outstanding common stock purchase warrants. The transaction involves the reduction of exercise prices on existing warrants and the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Expected Gross Proceeds: Approximately $3.9 million (excluding closing costs and fees).
- Existing Warrants Exercised: 4,318,905 warrants (comprising warrants issued in July 2022, February 2024, May 2024, and December 2024).
- Shares Issued on Exercise: 4,318,905 shares of common stock.
- New Exercise Price: Reduced to $0.9047 per share for the exercised warrants.
- New Warrant Issuance: One unregistered warrant issued to the Holder for 200% of the shares issued upon exercise (up to 8,637,810 shares).
- New Warrant Terms: Exercise price of $0.9047; 5-year term; exercisable after stockholder approval.
- Placement Agent Compensation:
- Cash fee: 8% of gross proceeds.
- Management fee: 1% of gross proceeds.
- Warrant: 6% of aggregate shares issued (exercise price $1.4928, 5-year term).
- Expenses: Up to $75,000.
Note: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes and Conditions
The primary material change is the dilution of existing shareholders due to the issuance of 4,318,905 shares from the warrant exercise and the potential issuance of up to 8,637,810 additional shares via the New Warrant. The transaction is subject to the following conditions:
- Stockholder Approval: Required by Nasdaq rules. The Company must hold a meeting within 60 days of July 23, 2025, to obtain approval. If not obtained, meetings must be held every 60 days thereafter.
- Beneficial Ownership Limitations: Issuance may be held in abeyance if the Holder would exceed beneficial ownership limits contained in the Existing Warrants.
- Registration: The Company must file a resale registration statement within 30 days and use commercially reasonable efforts to have it effective within 60 days.
- Lock-up/Blackout: For 30 days following July 23, 2025, the Company cannot enter into more favorable warrant inducement agreements or issue other common stock/equivalents.
Outlook, Risks, and Contingencies
- Liquidated Damages: The Company is liable for liquidated damages if the New Warrant shares are not registered for resale or if restrictive legends are not removed timely.
- Cashless Exercise Contingency: If shares underlying the New Warrant are not registered for resale six months after issuance, the New Warrant may be exercised on a cashless basis.
- Anti-Dilution Provisions: The New Warrant includes standard anti-dilution adjustments for stock splits, dividends, and fundamental transactions but lacks price protection for future securities offerings.
- Closing Date: Expected on or about July 25, 2025, subject to customary conditions.
Investor Verification Checklist
- Verify the status of the stockholder meeting scheduled within 60 days of July 23, 2025, to approve the issuance of New Warrant Shares.
- Confirm the filing and effectiveness of the Resale Registration Statement for the New Warrant shares within the required 30 and 60-day windows.
- Monitor the actual closing date and final gross proceeds received, as the $3.9 million figure is an estimate excluding fees.
- Review the full text of the Warrant Inducement Agreement (Exhibit 10.01) for specific liquidated damages calculations and beneficial ownership limitation thresholds.
- Assess the impact of the 200% bonus warrant issuance on future dilution and the company's capital structure.